- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Agenus Inc (AGEN)
Agenus Inc stock price live, this page displays NASDAQ AGEN stock exchange data. View the AGEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Agenus Inc real time stock price chart below.
What Is the Agenus Inc Stock Price Today?
The Agenus Inc stock price today is 2.830.
What Is the Stock Symbol for Agenus Inc?
The stock symbol for Agenus Inc is "AGEN."
What Stock Exchange Does Agenus Inc Trade On?
Agenus Inc is listed and trades on the NASDAQ stock exchange.
Is Agenus Inc a Good Stock to Buy?
Determining whether Agenus Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AGEN quote. (ISIN: US00847G8042)
What Is the Agenus Inc Stock Price Today?
The Agenus Inc stock price today is 2.830.
What Is the Stock Symbol for Agenus Inc?
The stock symbol for Agenus Inc is "AGEN."
What Stock Exchange Does Agenus Inc Trade On?
Agenus Inc is listed and trades on the NASDAQ stock exchange.
Is Agenus Inc a Good Stock to Buy?
Determining whether Agenus Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AGEN quote. (ISIN: US00847G8042)
2.830
-0.160(-5.35%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.805
2.950
52 wk Range
1.380
7.340
AGEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.8052.950
52 wk Range
1.3807.340
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AGEN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
12.333
Upside
+335.81%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 8K Agenus Inc For: 16 January
- Investing.com
- Form 8K Agenus Inc For: 16 January
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Agenus Inc Company Profile
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Agenus Inc Earnings Call Summary for Q2/2025
- Agenus pursuing accelerated approval for BotVal immunotherapy; stock up 154% in 6 months, trading at $4.66
- Collaborating with Zydis Corporation to enhance manufacturing; initiating Phase III BATMAN trial with Canadian Cancer Trials Group
- Focus on colorectal cancer treatment, developing second-generation CTLA-4 immunotherapy and iNKT cell technology
- Preparing for ESMO presentation; CEO emphasizes ambitious goals beyond incremental improvements
- Revenue and EPS not disclosed; ongoing discussions for potential financing transactions noted
Last Updated: 2025-09-12, 11:40 a/m
Read Full TranscriptCompare AGEN to Peers and Sector
Metrics to compare | AGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.7x | −1.6x | −0.6x | |
PEG Ratio | −0.03 | 0.07 | 0.00 | |
Price/Book | −0.3x | 1.6x | 2.6x | |
Price / LTM Sales | 0.9x | 14.1x | 3.4x | |
Upside (Analyst Target) | 167.6% | 358.1% | 44.4% | |
Fair Value Upside | Unlock | 10.8% | 6.1% | Unlock |
Analyst Ratings
2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 12.333
(+335.81% Upside)
Earnings
Latest Release
Nov 10, 2025
EPS / Forecast
1.94 / -0.28
Revenue / Forecast
30.24M / --
People Also Watch
FAQ
What Is the Agenus (AGEN) Stock Price Today?
The Agenus stock price today is 2.830
What Stock Exchange Does Agenus Trade On?
Agenus is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Agenus?
The stock symbol for Agenus is "AGEN."
What Is the Agenus Market Cap?
As of today, Agenus market cap is 95.90M.
What Is Agenus's Earnings Per Share (TTM)?
The Agenus EPS (TTM) is -1.32.
From a Technical Analysis Perspective, Is AGEN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Agenus Stock Split?
Agenus has split 2 times.
How Many Employees Does Agenus Have?
Agenus has 316 employees.
What is the current trading status of Agenus (AGEN)?
As of Jan 31, 2026, Agenus (AGEN) is trading at a price of 2.830, with a previous close of 2.990. The stock has fluctuated within a day range of 2.805 to 2.950, while its 52-week range spans from 1.380 to 7.340.
What Is Agenus (AGEN) Price Target According to Analysts?
The average 12-month price target for Agenus is USD12.333, with a high estimate of USD23 and a low estimate of USD6. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +335.81% Upside potential.
What Is the AGEN After Hours Price?
AGEN's last after hours stock price is 2.840, the stock has decreased by -0.150, or -5.020%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.